Measurement of Chronicity and Activity in Sjögren’s Syndrome

  • Claudio Vitali


Systemic autoimmune conditions such as Sjögren’s syndrome (SS) are commonly characterized by prolonged episodes of activity, sustained by the underlying immunologic and inflammatory processes [1, 2]. The activity flares are clinically marked by the new appearance or worsening of signs and symptoms that are typical for each one of the different diseases. In some diseases, elevation of acute phase reactants or abnormalities of immunologic markers accompany active periods. If the active phase of the disease does not remit spontaneously or if remission is not achieved by treatment, a chronic phase of the disease may begin and irreversible damage can be produced in the involved organs and systems [1, 2].


Damage Index Systemic Autoimmune Disease Clinical Vignette Activity Flare Steering Committee Member 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Symmonds DPM. Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol. 1995;9:267–85.CrossRefGoogle Scholar
  2. 2.
    Fries JF, Hochberg MC, Medsger TA. Criteria for rheumatic diseases: different types and different functions. Arthritis Rheum. 1994;37:454–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Liang MH. Translating outcomes measurement in experimental therapeutics of systemic rheumatic disease to patient care. Rheum Dis Clin North Am. 2006;32:1–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren’s syndrome: why autoimmune epithelitis? Oral Dis. 2006;12:523–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Garcia-Carrasco M, Ramos Casals M, Rasas J, et al. Primary Sjögren’s syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81:270–80.CrossRefGoogle Scholar
  6. 6.
    Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long term risk of mortality and lymphoproliferative diseases and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46:741–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjögren’s syndrome. Rheumatology (Oxford). 2007;46:1389–96.CrossRefGoogle Scholar
  8. 8.
    Looney RJ. Will targeting B cells be the answer for Sjögren’s syndrome. Arthritis Rheum. 2007;56:1371–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Szororay P, Jonnson R. The BAFF/APRIL system in systemic autoimmune diseases with special emphasis on Sjögren’s syndrome. Scand J Immunol. 2005;62:421–8.CrossRefGoogle Scholar
  11. 11.
    Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol. 2005;23 Suppl 39:S1–9.PubMedGoogle Scholar
  13. 13.
    Liang MH, Socher SA, Neal Roberts W, et al. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988;31(7):817–25.PubMedCrossRefGoogle Scholar
  14. 14.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418–26.CrossRefGoogle Scholar
  15. 15.
    Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol. 2003;17:753–81.PubMedCrossRefGoogle Scholar
  16. 16.
    Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol. 1999;26:490–7.PubMedGoogle Scholar
  17. 17.
    Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.PubMedCrossRefGoogle Scholar
  19. 19.
    van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261–3.PubMedGoogle Scholar
  20. 20.
    Vitali C, Palombi G, Baldini C, et al. Sjögren’s syndrome disease damage index and disease activity index. Scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56:2223–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol. 1992;10:541–7.PubMedGoogle Scholar
  22. 22.
    Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjögren’s Syndrome Clinical Activity Index (SCAI) – a systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. Rheumatology (Oxford). 2007;46:1845–51.CrossRefGoogle Scholar
  23. 23.
    Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86: 447–58.PubMedGoogle Scholar
  24. 24.
    Sutcliffe N, Stoll T, Pyke S, et al. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren’s syndrome (SS), and primary SS. J Rheumatol. 1998;25:63–8.PubMedGoogle Scholar
  25. 25.
    Barry RJ, Sutcliffe N, Isenberg DA, et al. The Sjögren’s syndrome Damage Index (SSDI) – a damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome. Rheumatology (Oxford). 2008;47:1193–8.CrossRefGoogle Scholar
  26. 26.
    Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69:1103–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjogren’s syndrome by the European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index. Arthritis Care Res. 2010;62:551–8.CrossRefGoogle Scholar
  28. 28.
    Bowman SJ, Booth DA, Platts RG. Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology (Oxford). 2004;43: 758–64.CrossRefGoogle Scholar
  29. 29.
    Bowman SJ, Booth DA, Platts RG, et al. Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren’s syndrome. J Rheumatol. 2003;30:1259–66.PubMedGoogle Scholar
  30. 30.
    Seror R, Ravaud P, Mariette X, et al. EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). Development of a consensus patient index for primary Sjögren’s syndrome. Ann Rheum Dis. 2011;70(6):968–72.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Claudio Vitali
    • 1
  1. 1.Department of Internal Medicine and Section of Rheumatology‘Villamarina’ HospitalPiombinoItaly

Personalised recommendations